Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

• Main Authors: Yazed AlRuthia (Author), Ohud H. Bahari (Author), Suliman Alghnam (Author), Ali M. Alrumaih (Author), Hassan Asiri (Author), Mohammed Alshammari (Author), Mansour Alhowimel (Author), Hana A. Al-Abdulkarim (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundThe advent of Basaglar®, which is a biosimilar insulin glargine formulation for Lantus® has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeutic equivalence of this new biosimilar. Therefore, we...